Patent intelligence · US
US 11986471
Compounds and methods of use
Compounds and methods of use
Patent details — US 11986471
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 21, 2024
- Expiration
- May 16, 2044
- Applicant
- Tango Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/4725, A61K31/496, A61K31/5377
Quick answer
US 11986471 (Compounds and methods of use) is held by Tango Therapeutics, Inc.. Status: granted. Granted May 21, 2024. Expires May 16, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tango Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/4725, A61K31/496, A61K31/5377, A61K31/5386
More from Tango Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403137
Compounds and methods of use
granted -
US 12304907
Compounds and methods of use
granted -
US 12264154
Compounds and methods of use
granted -
US 12043607
HDAC inhibitors and therapeutic use thereof
granted -
US 11999727
Compounds and methods of use
granted -
US 11492350
Compounds and methods of use
granted -
US 11077101
Compounds and methods of use
granted
Frequently asked questions
What is US patent 11986471?
US 11986471 (Compounds and methods of use) is held by Tango Therapeutics, Inc.. Status: granted. Granted May 21, 2024. Expires May 16, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11986471?
Tango Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 11986471 expire?
Our index shows an expiration date of May 16, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.